Table 1. Antiviral Activities of Target Compounds 1–16 against TMV in Vivo at 500 mg/L^a,d.

compound	curative effect activitya (%)	protection effect activitya (%)	inactivation effect activitya (%)
1	34.0 ± 4.4	31.7 ± 1.4	64.8 ± 8.5
2	39.8 ± 0.8	59.7 ± 6.2	87.3 ± 2.5
3	36.8 ± 8.0	40.4 ± 9.7	68.4 ± 7.0
4	26.9 ± 4.1	31.2 ± 9.2	56.6 ± 10.2
5	30.2 ± 2.6	38.5 ± 7.7	45.1 ± 7.4
6	50.3 ± 1.9	32.7 ± 5.7	59.8 ± 7.4
7	57.9 ± 10.3	53.3 ± 1.3	77.7 ± 8.1
8	31.9 ± 8.6	38.3 ± 7.9	54.6 ± 6.8
9	37.3 ± 2.0	41.0 ± 5.7	76.9 ± 5.4
10	41.4 ± 3.4	49.8 ± 8.3	74.1 ± 7.4
11	35.4 ± 3.2	38.9 ± 6.3	72.1 ± 7.5
12	55.3 ± 2.9	53.7 ± 9.9	65.2 ± 7.6
13	32.8 ± 2.3	53.7 ± 9.2	71.1 ± 8.0
14	50.6 ± 4.7	52.7 ± 8.6	64.6 ± 8.1
15	30.6 ± 2.7	38.7 ± 9.5	43.7 ± 3.8
16	47.1 ± 6.1	55.9 ± 1.9	73.7 ± 8.2
ningnanmycinb	56.6 ± 6.8	54.1 ± 3.4	88.3 ± 4.3
ribavirinc	49.3 ± 7.5	48.6 ± 2.5	72.7 ± 4.7

^aAverage of three replicates at 500 μg/mL.

^bNingnanmycin.

^cRibavirin was used as the control.

^dThe ± values represent the standard deviation.